Diagnostic and neutralizing aptamers technology against Sars-Cov-2

Zhiling Guo

doi:10.1117/12.2669355

24 March 2023 Diagnostic and neutralizing aptamers technology against Sars-Cov-2

Zhiling Guo

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 1261125 (2023) https://doi.org/10.1117/12.2669355
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

Severe acute respiratory syndrome coronavirus 2 (Sars-Cov-2) variants in a perpetual state of evolution are persistently challenging the development of medical therapeutics. Continuing beyond the mutation escape of variants requires a specific, stable, point-of-care, modifiable, and low-cost therapeutic reagent for both prophylactic treatment and clinical treatment. The nucleic acid-based approach, aptamer, has become one of the most competitive candidates for this highdemand anti-covid treatment. As current substantial research has consolidated its optimistic biosensor role in the field of detection and diagnostics for Sars-Cov-2, it is undoubtedly worth exploring aptamers as neutralizing agents. The applicability of aptamers with refined advantages should not only allow more possibilities in screening and diagnosis but also confer promising capabilities in neutralization, chimeric therapy, delivery, and vaccines for COVID-19. Therefore, the paper, through the method of literature review, reveals the current state of coronavirus and aptamer, summarizes the recent developments in theranostic aptamers, anti-Sars-Cov-2 neutralizing aptamers, and combined aptamers, and the prospect of aptamer research, including its challenges and focus. The paper concludes that aptamer-based biosensors, rapid antigen tests, and treatments are promising priorities against COVID-19 as diagnostic-aimed and neutralizing-aimed aptamers have been developed during the past two years. Although RBD-targeted and multivalent aptamers partly dampen the burden of nonspecificity and low effectivity, pushing into the “in vivo” testing stage and tackling frequent mutation escape should be the future research focus.

Citation Download Citation

Zhiling Guo "Diagnostic and neutralizing aptamers technology against Sars-Cov-2", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 1261125 (24 March 2023); https://doi.org/10.1117/12.2669355

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
11 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Proteins

Diagnostics

Therapeutics

COVID 19

Antibodies

Monoclonal antibodies

Gold nanoparticles

Show All Keywords

Keywords/Phrases

Search In:

Publication Years